Assessment of the Efficacy of a Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia
Assessment of the Efficacy of a Highly Standardized Ginger and Perilla Nutraceutical (Dispepril®) in Improving Gastric and Intestinal Symptoms in Patients With Functional Dyspepsia: A Multicenter, Randomized, Controlled Clinical Trial
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Functional dyspepsia (FD) is a common disorder of gut-brain interaction characterized by chronic or recurrent upper gastrointestinal symptoms in the absence of an identifiable organic cause. Typical symptoms include postprandial fullness, early satiety, epigastric pain, epigastric burning, upper abdominal bloating, belching, nausea, and heartburn. FD is associated with impaired quality of life and significant healthcare burden.
Current management strategies include proton pump inhibitors (PPIs), eradication of Helicobacter pylori when present, and prokinetic therapies. However, treatment efficacy is often limited, and long-term pharmacological therapy may be associated with adverse effects.
Dispepril® is a food supplement containing a highly standardized extract of Zingiber officinale titrated in gingerols and shogaols together with a patented bi-fractionated extract of Perilla frutescens. Ginger has been reported to normalize gastric emptying and improve dyspeptic symptoms, while perilla may exert prokinetic and anti-dyspeptic effects through actions on gastrointestinal motility.
This multicenter, prospective, randomized, controlled clinical trial will evaluate the efficacy of Dispepril® in adults diagnosed with functional dyspepsia according to Rome IV criteria. Approximately 400 participants will be enrolled and randomized in a 2:1:1 ratio into one of three treatment groups:
Dispepril® alone (two gastro-protected tablets daily for 14 days); Half-dose PPI once daily plus Dispepril® (two tablets daily for 14 days); Full-dose PPI once daily for 14 days.
The primary objective is to evaluate the non-inferiority of Dispepril® compared with PPI therapy in reducing postprandial distress symptoms. Efficacy will be assessed using the validated Leuven Postprandial Distress Scale (LPDS) at baseline and after 14 days of treatment.
Secondary objectives include evaluation of the synergistic activity of Dispepril® combined with half-dose PPI, assessment of treatment effects on individual LPDS gastrointestinal symptom items, treatment tolerability, therapeutic adherence, and adverse events.
The total duration of participation for each subject will be 14 days, with assessments performed at baseline (Day 0) and at the end of treatment (Day 14).
Studietype
Registrering (Antatt)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Montevarchi, Italia
- U.O.S.D. Digestive Endoscopy, Interventional and Emergency Unit
-
Rome, Italia
- University of Rome Tor Vergata
-
Salerno, Italia
- Gastroenterology Centre
-
Urbino, Italia
- University of Urbino Carlo Bo
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Beskrivelse
Inclusion Criteria:
- Male or female participants aged 18 to 65 years
- Diagnosis of functional dyspepsia according to Rome IV criteria
- Willingness and ability to provide written informed consent
- Ability to follow study product administration instructions
- Ability to attend scheduled study visits
Exclusion Criteria:
- Gastrectomy
- Cancer
- Use of NSAIDs, cholagogues, or tricyclic antidepressants within 30 days prior to enrollment
- Helicobacter pylori positivity
- Alcoholism or other substance abuse
- Hepatic disease
- Renal disease
- History of hypersensitivity to formulation active ingredients or excipients
- Pregnancy or breastfeeding
- Participation in another clinical trial or completion of another clinical trial within 1 month prior to enrollment
- Refusal or inability to provide informed consent
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Dispepril®
Participants will receive Dispepril®, administered as two gastro-protected tablets daily for 14 consecutive days.
One tablet will be taken approximately 15 minutes before lunch and one tablet approximately 15 minutes before dinner.
Each tablet contains 300 mg of highly standardized Zingiber officinale extract and 150 mg of a patented bi-fractionated Perilla frutescens extract.
|
Dispepril® is a gastro-protected dietary supplement containing 300 mg of highly standardized Zingiber officinale extract titrated to 10% gingerols and shogaols and 150 mg of a patented bi-fractionated Perilla frutescens extract per tablet.
Andre navn:
|
|
Eksperimentell: Half-Dose PPI Plus Dispepril®
Participants will receive a half-dose proton pump inhibitor once daily together with Dispepril® administered as two gastro-protected tablets daily for 14 consecutive days.
One tablet will be taken approximately 15 minutes before lunch and one tablet approximately 15 minutes before dinner.
|
Participants will receive a half-dose proton pump inhibitor once daily together with Dispepril® administered as two gastro-protected tablets daily for 14 consecutive days.
Andre navn:
|
|
Aktiv komparator: Full-Dose PPI
Participants will receive a full-dose proton pump inhibitor once daily for 14 consecutive days according to standard clinical practice for functional dyspepsia.
|
Participants will receive a full-dose proton pump inhibitor once daily for 14 consecutive days according to standard clinical practice for functional dyspepsia.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Post-Prandial Distress Assessed by the Leuven Postprandial Distress Scale (LPDS) Distress Compared to PPIs
Tidsramme: 14 days
|
Change in post-prandial distress from baseline to Day 14, assessed using the validated Leuven Postprandial Distress Scale (LPDS).
The LPDS consists of 8 items assessing postprandial fullness, early satiety, upper abdominal bloating, epigastric pain, epigastric burning, belching, nausea, and heartburn.
Each item is rated on a scale from 0 to 4, where 0 indicates no symptom and 4 indicates a very severe symptom.
The LPDS has a maximum total score of 32 points.
|
14 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Individual Gastrointestinal Symptoms Assessed by the Leuven Postprandial Distress Scale
Tidsramme: 14 days
|
Change from baseline to Day 14 in the individual symptom scores assessed using the Leuven Postprandial Distress Scale (LPDS).
The LPDS consists of 8 items evaluating postprandial fullness, early satiety, upper abdominal bloating, epigastric pain, epigastric burning, belching, nausea, and heartburn.
Each item is scored from 0 to 4, where 0 indicates no symptom and 4 indicates a very severe symptom.
Individual symptom scores range from 0 to 4, with higher scores indicating more severe symptoms and worse outcomes.
Changes in individual symptom scores will be compared among treatment groups.
|
14 days
|
|
Evaluation of the Efficacy of Treatments on Individual Gastrointestinal Symptoms
Tidsramme: 14 days
|
Efficacy of treatments in the various study groups on the individual items of gastrointestinal symptomatology of the Leuven Postprandial Distress Scale (LPDS), assessed at the beginning and end of treatment.
|
14 days
|
|
Treatment Tolerability Assessed by Investigator Clinical Evaluation
Tidsramme: 14 days
|
Treatment tolerability at Day 14 as assessed by the investigator during the final clinical evaluation.
The outcome will be reported as the number and percentage of participants considered to have tolerated treatment without clinically significant safety concerns.
|
14 days
|
|
Therapeutic Adherence
Tidsramme: 14 days
|
Therapeutic adherence will be assessed at Day 14 by counting returned unused tablets and comparing the number of tablets taken with the number prescribed.
The outcome will be reported as the percentage of prescribed tablets taken during the 14-day treatment period.
|
14 days
|
|
Incidence of Treatment-Emergent Adverse Events
Tidsramme: 14 days
|
Number and percentage of participants experiencing one or more treatment-emergent adverse events during the 14-day treatment period.
Adverse events will be recorded and graded according to the Common Terminology Criteria for Adverse Events (CTCAE).
|
14 days
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 170_31marzo 2026_DISPEPRIL
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .